But wait, there is more... Gerald Commissiong @
Post# of 1418
(Total Views: 278)
Posted On: 03/02/2022 10:29:45 AM
But wait, there is more...
Gerald Commissiong @G_Commish 2h
I have a lot to say regarding Biden’s team buying into our approach. Test to treat is the only path out. But you need way more tests and way more treatments for it to work. TolloTest, Tollovir and Tollovid (planning started to make OTC drug for outpatient) fit perfectly. $TOMDF
Gerald Commissiong @G_Commish 42m
There is no new shiny focus. It’s the natural evolution of Tollovid and part of the reason why Tollovid Daily deprioritized for time being. Many supplements have become OTC products once data is in hand. 3CL entity focus on Tollo products. Todos is testing revs+Videssa.
OTC Drug Monograph Process can be a quick path to market beyond the current supplement stream. Zicam sold for $.5B in 2020 and Tollovid/vir has a LOTTTT more going for it.
"OTC drug review process: Because of the vast number of OTC products out there, the FDA groups many OTC drugs into therapeutic categories and then issues a monograph for it. Under this process, any drug meeting the standards of this monograph can be marketed without a New Drug Application or premarket approval.
Drug application process: Any drug not meeting these standards must be approved through a New Drug Application (NDA) before it can be marketed as an OTC drug. This is the same process as prescription drug approval."
https://www.goodrx.com/hcp/providers/over-the...upplements
Over-the-Counter (OTC) Drug Monograph Process
https://www.fda.gov/drugs/over-counter-otc-dr...ph-process
Gerald Commissiong @G_Commish 2h
I have a lot to say regarding Biden’s team buying into our approach. Test to treat is the only path out. But you need way more tests and way more treatments for it to work. TolloTest, Tollovir and Tollovid (planning started to make OTC drug for outpatient) fit perfectly. $TOMDF
Gerald Commissiong @G_Commish 42m
There is no new shiny focus. It’s the natural evolution of Tollovid and part of the reason why Tollovid Daily deprioritized for time being. Many supplements have become OTC products once data is in hand. 3CL entity focus on Tollo products. Todos is testing revs+Videssa.
OTC Drug Monograph Process can be a quick path to market beyond the current supplement stream. Zicam sold for $.5B in 2020 and Tollovid/vir has a LOTTTT more going for it.
"OTC drug review process: Because of the vast number of OTC products out there, the FDA groups many OTC drugs into therapeutic categories and then issues a monograph for it. Under this process, any drug meeting the standards of this monograph can be marketed without a New Drug Application or premarket approval.
Drug application process: Any drug not meeting these standards must be approved through a New Drug Application (NDA) before it can be marketed as an OTC drug. This is the same process as prescription drug approval."
https://www.goodrx.com/hcp/providers/over-the...upplements
Over-the-Counter (OTC) Drug Monograph Process
https://www.fda.gov/drugs/over-counter-otc-dr...ph-process
(1)
(0)Todos Med Ltd. (TOMDF) Stock Research Links
Scroll down for more posts ▼